2022 Pivotal Points in Pediatric Atopic Dermatitis: What You Probably Missed But Shouldn’t Have

Target Audience
This educational activity has been designed to meet the needs of pediatric dermatologists, dermatologists, pediatricians, family practice physicians, nurse practitioners, physician assistants, and other clinicians who manage pediatric patients with atopic dermatitis.

Program Overview
2022 has been a banner year for patients with pediatric atopic dermatitis (AD) as well as for their parents, families, and healthcare providers. The biologic dupilumab was approved for moderate to severe AD for ages 6 months to 5 years. Adolescents with AD also got new treatment options with approvals of oral systemic and topical JAK inhibitors, upadacitinib and ruxolitinib, respectively. There are also biologics and JAK inhibitors that are now in phase 3 clinical trials for children and adolescents with AD.

Join pediatric AD expert, Dr. Peter Lio, as he discusses pivotal trials from 2022 to highlight the new and emerging treatment for children and adolescents with AD.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Incorporate new biologic and small-molecule treatments for appropriately selected children and adolescents with AD that have not responded adequately to other medications
Review clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD